Anannya Patwari

Anannya Patwari

Auto-generated profile, based on publicly available information

Anannya Patwari

MCW Cancer Center and Genomic Sciences and Precision Medicine Center, Medical College of Wisconsin, Milwaukee, WI

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 March 2021 in Journal of Cancer Research and Clinical Oncology
Verified
Journal Article
Closed access
PDF file
VBVineel Bhatlapenumarthi
Vineel Bhatlapenumarthi
APAnannya Patwari
Anannya Patwari
AHAntoine J. Harb
Antoine J. Harb

1 January 2026 in JCO Oncology Advances
Verified
Journal Article
Closed access
APAnannya Patwari
Anannya Patwari
DNDaisuke Nishizaki
Daisuke Nishizaki
TJTaylor Jensen
Taylor Jensen
PDPaul DePietro
Paul DePietro
SPSarabjot Pabla
Sarabjot Pabla
RKRazelle Kurzrock
Razelle Kurzrock
PURPOSE: PD-L1 and PD-L2 are inhibitory ligands that interact with PD-1 receptors, enabling immune escape. Although PD-L1 has been extensively studied, much less is known about PD-L2. PD-L2 expression could lead to incomplete blockade of the PD-1 axis by anti–PD-L1 agents and also influence the activity of anti–PD-1 agents. METHODS: We analyzed PD-L2 transcriptomic expression in a pan-cancer cohort (N = 514; 489 patients with advanced/metastatic disease and clinical correlates available) for associations with immunomodulatory variables and outcome. RESULTS: The most common tumors were colorectal (27% [140 of 514]), pancreatic (11% [55 of 514]), and breast cancer (9.5% [49 of 514]). High PD-L2 expression (≥75th RNA percentile rank) occurred in 19.5% (100 of 514) of patients; PD-L2 expression varied across and within tumor types. High PD-L2 independently/significantly correlated with high PD-L1, PD-1, CD4, and T-cell immunoglobulin and mucin-containing protein 3 (TIM-3) RNA levels (both as dichotomized and linear variables), high tumor mutational burden (TMB; ≥10 mutations/Mb), and a breast cancer diagnosis. In 217 patients who received immune checkpoint blockade (mainly anti–PD-1-based regimens), high versus moderate/low PD-L2 predicted longer overall survival (OS) (but not progression-free survival) in univariate analysis (median, 1.88 years [95% CI, 1.37 to not estimable] versus 1.21 years [95% CI, 0.95 to 1.54]; P = .02). In 272 patients who never received immunotherapy, high PD-L2 expression was not prognostic for OS. CONCLUSION: High PD-L2 transcripts were more common in breast cancer and associated with high expression of other immune-relevant factors: PD-L1, PD-1, CD4, and TIM-3, and with TMB ≥10 mutations/Mb. High PD-L2 levels correlated with longer OS in immunotherapy-treated patients.

31 August 2020 in The Breast Journal
Verified
Journal Article
Closed access
APAnannya Patwari
Anannya Patwari
VBVineel Bhatlapenumarthi
Vineel Bhatlapenumarthi